DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Faropenem is an investigational drug.
There have been 8 clinical trials for Faropenem. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2005.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and Pneumonia, Bacterial. The leading clinical trial sponsors are National University Hospital, Singapore, Replidyne, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recent Clinical Trials for Faropenem
|Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers||National University Hospital, Singapore||Phase 2|
|Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB||Johns Hopkins University||Phase 2|
|Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers||National University Hospital, Singapore||Phase 1|